MIKICORT (budesonide), corticosteroid for local use

No clinical benefit demonstrated in the management of autoimmune hepatitis when compared with systemic corticosteroids

• MIKICORT has obtained an extension of indication in the induction of remission and the maintenance treatment for autoimmune hepatitis.
• Data on long-term tolerability and efficacy are limited.
• Its use in combination with azathioprine should be reserved for noncirrhotic patients with a relative contraindication to systemic corticosteroid therapy or to corticosteroid replacement therapy in the event of the onset of adverse effects.